Autologous T Cell Manufacturing via Single-Cycle Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing process for producing autologous engineered T cells for cancer therapy is lengthy, involving two cycles of retroviral transduction and is not well-suited for commercial applications due to its complexity and duration.
Innovation Solution
A method is developed to enrich lymphocytes, stimulate them with T-cell stimulating agents in a closed system using serum-free culture medium, transduce them with a viral vector in a single cycle using a closed bag system coated with recombinant human fibronectin, and expand the cells to produce engineered T cells that recognize specific antigenic moieties on target cells, such as cancer cells, within a significantly shorter timeframe.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the existing process for producing autologous engineered T cells is used, then the T cells can be produced with the required biological activity, but the production time is lengthy (10-24 days) and the process complexity is high
Solution Approach 1:
The patent changes key process parameters including using a single cycle of retroviral transduction instead of two cycles, performing all steps in closed systems, and using serum-free culture medium. These parameter changes reduce production time to 6-10 days while maintaining T cell biological activity and functionality.
Solution Approach 2:
The patent segments the production process into distinct closed system modules: lymphocyte enrichment, T cell activation, retroviral transduction, and cell expansion. Each segment is performed in a separate closed system, reducing contamination risks and enabling parallel processing to shorten overall production time.
2Productivity
If the existing process is used, then T cells can be produced, but the process is poorly suited for commercial applications due to complexity and duration
Solution Approach 1:
The patent simplifies the process by changing to a single cycle transduction protocol and using standardized closed system culture bags with serum-free medium. These changes reduce procedural complexity while increasing productivity, making the process suitable for commercial manufacturing.
Solution Approach 2:
The patent uses disposable closed system culture bags for all cell manipulation steps. This eliminates the need for complex sterilization and cleaning procedures between uses, reducing process complexity and enabling high-throughput commercial production.
3Reliability
If traditional open systems with serum are used, then cell culture can be performed, but contamination risks increase and serum availability may be limited
Solution Approach 1:
The patent uses closed system culture bags that create a controlled, sterile environment for cell culture. This inert protective environment prevents contamination while maintaining cell viability, and the closed design simplifies manufacturing by eliminating the need for complex sterilization protocols.
Solution Approach 2:
The patent replaces serum-containing media with serum-free culture medium in the closed system. This change eliminates serum-related contamination risks and variability while maintaining T cell growth and function, simplifying the manufacturing process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method reduces the production time to approximately 6 days, enhances the efficiency of T cell manufacturing, and maintains the biological activity and phenotypic profile of the cells, making it suitable for clinical and commercial applications while minimizing contamination risks and serum use.
Implementation Method 1
transducing the population of activated T cells with a viral vector comprising a nucleic acid molecule which encodes the cell surface receptor
Implementation Method 2
wherein the bag is coated with a recombinant human fibronectin protein or fragment thereof
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are methods for manufacturing T cells. In certain embodiments, methods for manufacturing T cells which express a cell surface receptor that recognizes a specific antigenic moiety on the surface of a target cell are provided. Such methods may include, but are not limited to, steps of (1 ) enriching a population of lymphocytes obtained from a donor subject; (2) stimulating the population of lymphocytes with one or more T-cell stimulating agents to produce a population of activated T cells, wherein the stimulation is performed in a closed system using serum-free culture medium; (3) transducing the population of activated T cells with a viral vector comprising a nucleic acid molecule which encodes the cell surface receptor, using a single cycle transduction to produce a population of transduced T cells, wherein the transduction is performed in a closed system using serum-free culture medium; and (4) expanding the population of transduced T cells for a predetermined time to produce a population of engineered T cells, wherein the expansion is performed in a closed system using serum-free culture medium. Also provided herein are populations of engineered T cells produced by the methods described herein and pharmaceutical compositions thereof.